{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:15:16Z","timestamp":1790691316851,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ijrobp.2015.07.005","type":"journal-article","created":{"date-parts":[[2015,7,11]],"date-time":"2015-07-11T04:59:08Z","timestamp":1436590748000},"page":"569-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients"],"prefix":"10.1016","volume":"93","author":[{"given":"Elin","family":"Cederkrantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kan","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"B\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnar","family":"Hultborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Jacobsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sture","family":"Lindegren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ljungberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Magnander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig","family":"Palm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Albertsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.07.005_bib1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3389\/fonc.2013.00324","article-title":"The potential and hurdles of targeted alpha therapy: Clinical trials and beyond","volume":"3","author":"Elgqvist","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.nucmedbio.2006.07.009","article-title":"Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: Therapeutic efficacy and myelotoxicity","volume":"33","author":"Elgqvist","year":"2006","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s00259-011-2023-6","article-title":"Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis","volume":"39","author":"Essler","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib4","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","article-title":"Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: Comparing efficacy with 213Bi and 90Y","volume":"69","author":"Song","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib5","first-page":"1342","article-title":"Alpha-radioimmunotherapy of intraperitoneally growing Ovcar-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose","volume":"47","author":"Elgqvist","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib6","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: Pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2\u2013a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","article-title":"Dose escalation and dosimetry of first-in-human alpha radioimmunotherapy with 212Pb-TCMC--trastuzumab","volume":"55","author":"Meredith","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cbr.2013.1531","article-title":"Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients","volume":"29","author":"Meredith","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib9","first-page":"1131","article-title":"Modelling the biokinetics of intra-peritoneally administered targeted alpha therapy on patients for improved dosimetry","volume":"55","author":"Palm","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.ijrobp.2006.07.003","article-title":"Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2","volume":"66","author":"Elgqvist","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib11","first-page":"1","article-title":"The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103","volume":"37","year":"2007","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00411-002-0164-5","article-title":"Therapy of ankylosing spondylitis with 224Ra-radium chloride: Dosimetry and risk considerations","volume":"41","author":"Lassmann","year":"2002","journal-title":"Radiat Environ Biophys"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","article-title":"Dosimetry of 223Ra-chloride: Dose to normal organs and tissues","volume":"40","author":"Lassmann","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib14","first-page":"3","article-title":"Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas","volume":"8","author":"Yin","year":"2008","journal-title":"Cancer Immun"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib15","first-page":"37","article-title":"The study of phosphate transporter NaPi2b expression in different histological types of epithelial ovarian cancer","volume":"31","author":"Gryshkova","year":"2009","journal-title":"Exp Oncol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/PAI.0b013e318228e232","article-title":"In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody MX35","volume":"20","author":"Soares","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0969-8043(01)00044-6","article-title":"Dry-distillation of astatine-211 from irradiated bismuth targets: A time-saving procedure with high recovery yields","volume":"55","author":"Lindegren","year":"2001","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0969-8051(00)00171-2","article-title":"High-efficiency astatination of antibodies using n-iodosuccinimide as the oxidising agent in labelling of n-succinimidyl 3-(trimethylstannyl)benzoate","volume":"28","author":"Lindegren","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib19","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2967\/jnumed.107.049833","article-title":"Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate","volume":"49","author":"Lindegren","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib20","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1088\/0031-9155\/38\/8\/010","article-title":"Measuring astatine-211 distributions with SPECT","volume":"38","author":"Turkington","year":"1993","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib21","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1088\/0031-9155\/50\/17\/018","article-title":"A Monte Carlo and physical phantom evaluation of quantitative In-111 SPECT","volume":"50","author":"He","year":"2005","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1089\/cbr.2005.20.92","article-title":"The lundadose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy","volume":"20","author":"Sj\u00f6green","year":"2005","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib23","doi-asserted-by":"crossref","unstructured":"Frey E.C., Tsui B.M.W. A new method for modeling the spatially-variant, object-dependent scatter response function in spect. Nuclear Science Symposium, 1996. Conference Record, 1996 IEEE. 1996; pp. 1082\u20131086. vol.\u00a01082.","DOI":"10.1109\/NSSMIC.1996.591559"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib24","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1088\/0031-9155\/43\/4\/014","article-title":"Fast implementations of reconstruction-based scatter compensation in fully 3D SPECT image reconstruction","volume":"43","author":"Kadrmas","year":"1998","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0169-2607(89)90111-9","article-title":"A Monte Carlo program for the simulation of scintillation camera characteristics","volume":"29","author":"Ljungberg","year":"1989","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib26","first-page":"2061","article-title":"211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo","volume":"46","author":"B\u00e4ck","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib27","unstructured":"B\u00e9 M.M., Chist\u00e9 V., Dulieu C., et\u00a0al. Table of radionuclides, monographie bipm-5Gif-sur-Yvette and S\u00e8vres, France: CEA\/LNE-LNHB and BIPM;\u00a02011."},{"key":"10.1016\/j.ijrobp.2015.07.005_bib28","unstructured":"B\u00e9 M.M., Chist\u00e9 V., Dulieu C., et\u00a0al. Table of radionuclides, monographie bipm-5S\u00e8vres, France: BIPM;\u00a02013."},{"key":"10.1016\/j.ijrobp.2015.07.005_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","article-title":"Physical models and dose factors for use in internal dose assessment","volume":"85","author":"Stabin","year":"2003","journal-title":"Health Phys"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2015.07.005_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.icrp.2012.06.038","article-title":"ICRP publication 119: Compendium of dose coefficients based on ICRP publication 60","volume":"41","author":"Eckerman","year":"2012","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib31","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/0146645315576096","article-title":"Use of effective dose in medicine","volume":"44","author":"Harrison","year":"2015","journal-title":"Ann ICRP"},{"key":"10.1016\/j.ijrobp.2015.07.005_bib32","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00411-009-0227-y","article-title":"Incidence of leukaemia and other malignant diseases following injections of the short-lived alpha-emitter 224Ra into man","volume":"48","author":"Wick","year":"2009","journal-title":"Radiat Environ Biophys"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615007361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615007361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T18:37:51Z","timestamp":1599244671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615007361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0360301615007361"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.07.005","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorbed Doses and Risk Estimates of 211At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}